文献速递肾癌与肾肿瘤

机器人辅助肾部分切除术治疗伴静脉瘤栓的pT3a肾 masses的临床结局

Clinical Outcomes of Robotic Assisted Partial Nephrectomy for Pathologic T3a Renal Masses With Venous Tumor Thrombus.
PubMed 文献 · Urology · 2021-09-16

该回顾性研究评估了45例伴静脉瘤栓的pT3a肾细胞癌患者接受机器人辅助肾部分切除术(RPN)的安全性和早期肿瘤学结局。结果显示手术可行且安全,2年局部无复发生存率为95.4%,无转移生存率为95.3%,短期肿瘤学结局优于历史文献。

要点

  • RPN治疗pT3a伴静脉瘤栓的肾 masses在合适术者手中可行且安全
  • 2年局部无复发生存率95.4%,无转移生存率95.3%
  • 阳性切缘率6.7%,局部复发率4.4%,转移率8.9%

核心结论

  • RPN治疗pT3a伴静脉瘤栓的肾 masses可行且安全,短期肿瘤学结局优于历史文献。

研究设计与样本

  • 回顾性病历审查,纳入2009年9月至2020年7月接受RPN的45例pT3a伴静脉受累患者。

主要发现

  • 平均手术时间199.6±47.3分钟,平均热缺血时间30.5±10.5分钟,平均估计失血量324.9±209.5 cc。
  • 30天内输血率8.9%(4/45),栓塞率2.2%(1/45),再入院率11.1%(5/45),再手术率6.7%(3/45,均为膀胱镜支架置入)。
  • 所有肿瘤均为恶性,透明细胞肾细胞癌最常见(91.0%,n=41),阳性切缘率6.7%(n=3)。
  • 局部复发率4.4%(n=2),平均时间5.2±2.3个月;转移率8.9%(4例),平均时间22.2±23.0个月。
  • 2年局部无复发生存率95.4%,无转移生存率95.3%。

临床怎么用

  • 在经验丰富的术者中,RPN可作为pT3a伴静脉瘤栓肾 masses的一种可行且安全的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety, efficacy, and early oncologic outcomes of pathologic T3a (pT3a) renal cell carcinoma with venous involvement treated with robotic partial nephrectomy (RPN), given that experience and outcomes in this group is limited. METHODS: A retrospective chart review of patients undergoing RPN from September 2009 to July 2020 was performed. Outcomes were captured from patients with pT3a disease with vein involvement. Clinical characteristics were analyzed using SPSS (IBM, Armonk, NY). Local recurrence-free survival and metastasis-free survival at 2 years were calculated from Kaplan-Meier survival curves. RESULTS: For 45 included patients, mean operative and warm ischemia times were 199.6 ± 47.3 minutes and 30.5 ± 10.5 minutes, with mean estimated blood loss of 324.9 ± 209.5 cc. Rates of transfusion, embolization, re-admission, and re-operation at 30 days were 8.9% (4/45), 2.2% (1/45), 11.1% (5/45), and 6.7% (3/45; cystoscopic stent placement), respectively. All tumors were malignant on pathology, with clear cell renal cell carcinoma being the most common (91.0%, n = 41). The positive margin rate was 6.7% (n = 3). Local recurrence occurred in 4.4% (n = 2) at a mean time of 5.2 ± 2.3 months. Four patients (8.9%) progressed to metastatic disease at a mean of 22.2 ± 23.0 months. At 2 years, local recurrence-free survival was 95.4% and metastasis-free survival was 95.3%. CONCLUSION: We present the largest known series of patients RPN for pT3a renal masses with venous tumor involvement. We found it both feasible and safe in the appropriate hands. Short term oncologic outcomes for these patients appear more favorable than historic literature suggested.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Morgan TN, Dai JC, Kusin S, et al. Clinical Outcomes of Robotic Assisted Partial Nephrectomy for Pathologic T3a Renal Masses With Venous Tumor Thrombus. Urology. 2021. PMID: 34537195. doi:10.1016/j.urology.2021.06.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。